JP2013522286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522286A5 JP2013522286A5 JP2012557645A JP2012557645A JP2013522286A5 JP 2013522286 A5 JP2013522286 A5 JP 2013522286A5 JP 2012557645 A JP2012557645 A JP 2012557645A JP 2012557645 A JP2012557645 A JP 2012557645A JP 2013522286 A5 JP2013522286 A5 JP 2013522286A5
- Authority
- JP
- Japan
- Prior art keywords
- oxa
- morpholino
- azaspiro
- heptan
- triazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 substituted Chemical class 0.000 claims 176
- 229910052757 nitrogen Inorganic materials 0.000 claims 23
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 12
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 9
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 8
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims 8
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 7
- 125000005647 linker group Chemical group 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 claims 5
- 108090001008 Avidin Proteins 0.000 claims 5
- GTCAXTIRRLKXRU-UHFFFAOYSA-N carbamic acid methyl ester Natural products COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims 5
- 239000004202 carbamide Substances 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 5
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 4
- YLXFUFFEENJTSM-WLRTZDKTSA-N (e)-3-[[6-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2,6-diazaspiro[3.3]heptan-2-yl]sulfonyl]-n,n-dimethylprop-2-en-1-amine Chemical compound C1N(S(=O)(=O)/C=C/CN(C)C)CC11CN(C=2N=C(N=C(N=2)N2CCOCC2)N2C3=CC=CC=C3N=C2C(F)F)C1 YLXFUFFEENJTSM-WLRTZDKTSA-N 0.000 claims 4
- SWVYUIBQZQZMIE-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]pyrimidin-2-yl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=NC=C(C=2N=C(N=C(N=2)N2CC3(COC3)C2)N2CCOCC2)C=N1 SWVYUIBQZQZMIE-UHFFFAOYSA-N 0.000 claims 4
- KTRSMJFXBRUEOW-UHFFFAOYSA-N 1-ethyl-3-[4-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]phenyl]urea Chemical compound C1=CC(NC(=O)NCC)=CC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 KTRSMJFXBRUEOW-UHFFFAOYSA-N 0.000 claims 4
- QKSBOAKCHDBTJX-UHFFFAOYSA-N 1-ethyl-3-[5-[4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]pyrimidin-2-yl]urea Chemical compound C1=NC(NC(=O)NCC)=NC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CC3CCC(O3)C2)=N1 QKSBOAKCHDBTJX-UHFFFAOYSA-N 0.000 claims 4
- YHCSLFITDABKFS-UHFFFAOYSA-N 1-ethyl-3-[5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]pyrimidin-2-yl]urea Chemical compound C1=NC(NC(=O)NCC)=NC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 YHCSLFITDABKFS-UHFFFAOYSA-N 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- FGWDPDRVMALKQQ-UHFFFAOYSA-N 4-[4-(2,6-diazaspiro[3.3]heptan-2-yl)-6-[2-(difluoromethyl)benzimidazol-1-yl]-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CC3(CNC3)C2)=NC=1N1CCOCC1 FGWDPDRVMALKQQ-UHFFFAOYSA-N 0.000 claims 4
- DZPYUIFUWHQOQW-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-1,3,5-triazin-2-yl]morpholine Chemical compound C1N(C)CC21CN(C=1N=C(N=C(N=1)N1CCOCC1)N1C3=CC=CC=C3N=C1C(F)F)C2 DZPYUIFUWHQOQW-UHFFFAOYSA-N 0.000 claims 4
- HDSVYQAJZCEMES-UHFFFAOYSA-N 5-[2-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyrimidin-2-amine Chemical compound FC(F)(F)C1=NC(N)=NC=C1C1=CC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 HDSVYQAJZCEMES-UHFFFAOYSA-N 0.000 claims 4
- IHLJZIDKFWNTGW-UHFFFAOYSA-N 5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]pyridin-2-amine Chemical compound C1=NC(N)=CC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 IHLJZIDKFWNTGW-UHFFFAOYSA-N 0.000 claims 4
- BENZYCCSYXXLCM-UHFFFAOYSA-N 5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-2-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CC3(COC3)C2)=CC(N2CCOCC2)=N1 BENZYCCSYXXLCM-UHFFFAOYSA-N 0.000 claims 4
- NYFQPEZMHRTICP-UHFFFAOYSA-N 5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-2-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=NC(N2CC3(COC3)C2)=CC(N2CCOCC2)=N1 NYFQPEZMHRTICP-UHFFFAOYSA-N 0.000 claims 4
- PGPHXOGMZSAAHC-UHFFFAOYSA-N 6-[2-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-4-yl]-2-oxa-6-azaspiro[3.3]heptane Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CC3(COC3)C2)=CC=1N1CCOCC1 PGPHXOGMZSAAHC-UHFFFAOYSA-N 0.000 claims 4
- VQVDZAUJPNKGQL-UHFFFAOYSA-N 6-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2-oxa-6-azaspiro[3.3]heptane Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CC3(COC3)C2)=NC=1N1CCOCC1 VQVDZAUJPNKGQL-UHFFFAOYSA-N 0.000 claims 4
- SGTSWFVOBPYMTJ-UHFFFAOYSA-N 6-[6-[2-(difluoromethyl)benzimidazol-1-yl]-2-morpholin-4-ylpyrimidin-4-yl]-2-oxa-6-azaspiro[3.3]heptane Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=CC(N2CC3(COC3)C2)=NC=1N1CCOCC1 SGTSWFVOBPYMTJ-UHFFFAOYSA-N 0.000 claims 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 4
- 239000005977 Ethylene Substances 0.000 claims 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- PGZSVGZNVSYTHM-CALCHBBNSA-N [5-[4-[(3r,5s)-3,5-dimethylmorpholin-4-yl]-2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrido[2,3-d]pyrimidin-7-yl]-2-methoxyphenyl]methanol Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3CC4(COC4)C3)N3[C@@H](COC[C@@H]3C)C)C2=N1 PGZSVGZNVSYTHM-CALCHBBNSA-N 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 229960002685 biotin Drugs 0.000 claims 4
- 235000020958 biotin Nutrition 0.000 claims 4
- 239000011616 biotin Substances 0.000 claims 4
- 125000005708 carbonyloxy group Chemical group [*:2]OC([*:1])=O 0.000 claims 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 4
- 125000002228 disulfide group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 4
- 239000007790 solid phase Substances 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- OQEYBFLDTBSKDT-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[4-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]phenyl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CC3(COC3)C2)N2CCOCC2)C=C1 OQEYBFLDTBSKDT-UHFFFAOYSA-N 0.000 claims 3
- ZYKTZBLUXBSTGQ-UHFFFAOYSA-N 1-[6-[4-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2,6-diazaspiro[3.3]heptan-2-yl]-2-chloroethanone Chemical compound C1=NC(N)=NC=C1C1=NC(N2CC3(CN(C3)C(=O)CCl)C2)=NC(N2CCOCC2)=N1 ZYKTZBLUXBSTGQ-UHFFFAOYSA-N 0.000 claims 3
- QMGLZLGYZLHMIE-UHFFFAOYSA-N 1-methyl-3-[4-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]phenyl]urea Chemical compound C1=CC(NC(=O)NC)=CC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 QMGLZLGYZLHMIE-UHFFFAOYSA-N 0.000 claims 3
- KWOMZVDZXXUIPW-UHFFFAOYSA-N 2-chloro-1-[6-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2,6-diazaspiro[3.3]heptan-2-yl]ethanone Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CC3(CN(C3)C(=O)CCl)C2)=NC=1N1CCOCC1 KWOMZVDZXXUIPW-UHFFFAOYSA-N 0.000 claims 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- MMYZWPPNBQYXHH-UHFFFAOYSA-N 4-methyl-5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]pyridin-2-amine Chemical compound CC1=CC(N)=NC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 MMYZWPPNBQYXHH-UHFFFAOYSA-N 0.000 claims 3
- XHEPEPWLWYVDET-UHFFFAOYSA-N 4-methyl-5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]pyrimidin-2-amine Chemical compound CC1=NC(N)=NC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 XHEPEPWLWYVDET-UHFFFAOYSA-N 0.000 claims 3
- ZOOWSWDXGKELIV-UHFFFAOYSA-N 5-[2-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=CC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 ZOOWSWDXGKELIV-UHFFFAOYSA-N 0.000 claims 3
- RTDVHLWDOSQRBM-UHFFFAOYSA-N 5-[4-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]pyrimidin-2-amine Chemical compound C1N(C)CC21CN(C=1N=C(N=C(N=1)N1CCOCC1)C=1C=NC(N)=NC=1)C2 RTDVHLWDOSQRBM-UHFFFAOYSA-N 0.000 claims 3
- CUEVGTVGJCCNLE-UHFFFAOYSA-N 5-[4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CC3CCC(O3)C2)=N1 CUEVGTVGJCCNLE-UHFFFAOYSA-N 0.000 claims 3
- FDCFWOLVSCPZPM-UHFFFAOYSA-N 5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]pyrimidin-2-amine Chemical compound C1=NC(N)=NC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 FDCFWOLVSCPZPM-UHFFFAOYSA-N 0.000 claims 3
- HQEPONXNCLIYJB-UHFFFAOYSA-N 5-[6-morpholin-4-yl-2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CC3(COC3)C2)=N1 HQEPONXNCLIYJB-UHFFFAOYSA-N 0.000 claims 3
- MDOBZNMMEWMZDC-UHFFFAOYSA-N 6-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-ylpyrimidin-2-yl]-2-oxa-6-azaspiro[3.3]heptane Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=CC(N2CCOCC2)=NC=1N(C1)CC21COC2 MDOBZNMMEWMZDC-UHFFFAOYSA-N 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 3
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 3
- 108010090804 Streptavidin Proteins 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 3
- 125000005392 carboxamide group Chemical class NC(=O)* 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 239000002207 metabolite Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- HXCNWXXFEHKQMC-UHFFFAOYSA-N n-[2-[2-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2,6-diazaspiro[3.3]heptan-6-yl]ethyl]prop-2-enamide Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC(N2CC3(CN(CCNC(=O)C=C)C3)C2)=NC=1N1CCOCC1 HXCNWXXFEHKQMC-UHFFFAOYSA-N 0.000 claims 3
- 150000002829 nitrogen Chemical class 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- BLEQDYDNIVRHMS-VMPITWQZSA-N (e)-1-[6-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2,6-diazaspiro[3.3]heptan-2-yl]-4-(dimethylamino)but-2-en-1-one Chemical compound C1N(C(=O)/C=C/CN(C)C)CC21CN(C=1N=C(N=C(N=1)N1CCOCC1)N1C3=CC=CC=C3N=C1C(F)F)C2 BLEQDYDNIVRHMS-VMPITWQZSA-N 0.000 claims 2
- RCZNKLPZXMBEOE-UHFFFAOYSA-N 1-[6-[4-(2-aminopyrimidin-5-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]-2,6-diazaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound C1=NC(N)=NC=C1C1=NC(N2CC3(CN(C3)C(=O)C=C)C2)=NC(N2CCOCC2)=N1 RCZNKLPZXMBEOE-UHFFFAOYSA-N 0.000 claims 2
- WBHVIWTZHKYWMV-UHFFFAOYSA-N 1-methyl-3-[4-[4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]phenyl]urea Chemical compound C1=CC(NC(=O)NC)=CC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CC3CCC(O3)C2)=N1 WBHVIWTZHKYWMV-UHFFFAOYSA-N 0.000 claims 2
- PCCJBPIMDYFIGG-UHFFFAOYSA-N 2,6-dimethoxy-4-[1-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]imidazol-4-yl]phenol Chemical compound COC1=C(O)C(OC)=CC(C=2N=CN(C=2)C=2N=C(N=C(N=2)N2CC3(COC3)C2)N2CCOCC2)=C1 PCCJBPIMDYFIGG-UHFFFAOYSA-N 0.000 claims 2
- MHJOLISBSJBKTP-UHFFFAOYSA-N 2,6-dimethoxy-4-[5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]furan-2-yl]phenol Chemical compound COC1=C(O)C(OC)=CC(C=2OC(=CC=2)C=2N=C(N=C(N=2)N2CC3(COC3)C2)N2CCOCC2)=C1 MHJOLISBSJBKTP-UHFFFAOYSA-N 0.000 claims 2
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 claims 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- VCWVXIDQILXJFE-UHFFFAOYSA-N 3-[4-[2-(difluoromethyl)benzimidazol-1-yl]-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]-8-oxa-3-azabicyclo[3.2.1]octane Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=C(N=1)N2CC3CCC(O3)C2)=NC=1N(C1)CC21COC2 VCWVXIDQILXJFE-UHFFFAOYSA-N 0.000 claims 2
- LLXRHAKGKJMNRR-UHFFFAOYSA-N 4-pyrimidin-5-ylpyrimidine Chemical compound C1=NC=CC(C=2C=NC=NC=2)=N1 LLXRHAKGKJMNRR-UHFFFAOYSA-N 0.000 claims 2
- ZLHFHDYHFFPWEN-UHFFFAOYSA-N 5-[2-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 ZLHFHDYHFFPWEN-UHFFFAOYSA-N 0.000 claims 2
- CERXSOIRDZZUGF-UHFFFAOYSA-N 5-[4-(6-methyl-2,6-diazaspiro[3.3]heptan-2-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1N(C)CC21CN(C=1N=C(N=C(N=1)N1CCOCC1)C=1C(=CC(N)=NC=1)C(F)(F)F)C2 CERXSOIRDZZUGF-UHFFFAOYSA-N 0.000 claims 2
- NCWCRJGZBXZSFU-UHFFFAOYSA-N 5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyridin-2-amine Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=NC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 NCWCRJGZBXZSFU-UHFFFAOYSA-N 0.000 claims 2
- WJLMOWBUJZVEQB-UHFFFAOYSA-N 5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]-4-(trifluoromethyl)pyrimidin-2-amine Chemical compound FC(F)(F)C1=NC(N)=NC=C1C1=NC(N2CC3(COC3)C2)=NC(N2CCOCC2)=N1 WJLMOWBUJZVEQB-UHFFFAOYSA-N 0.000 claims 2
- FHKRRGHQZSKAQR-UHFFFAOYSA-N 5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-2-yl]-4-(trifluoromethyl)pyrimidin-2-amine Chemical compound FC(F)(F)C1=NC(N)=NC=C1C1=NC(N2CC3(COC3)C2)=CC(N2CCOCC2)=N1 FHKRRGHQZSKAQR-UHFFFAOYSA-N 0.000 claims 2
- CJUCILOHKFTZRE-UHFFFAOYSA-N 5-[6-morpholin-4-yl-2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrimidin-4-yl]-4-(trifluoromethyl)pyrimidin-2-amine Chemical compound FC(F)(F)C1=NC(N)=NC=C1C1=CC(N2CCOCC2)=NC(N2CC3(COC3)C2)=N1 CJUCILOHKFTZRE-UHFFFAOYSA-N 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 2
- PUHKUSYCOPZBGL-UHFFFAOYSA-N [2-methoxy-5-[4-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]methanol Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3CC4(COC4)C3)N3CC4CCC(O4)C3)C2=N1 PUHKUSYCOPZBGL-UHFFFAOYSA-N 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- UFWUDFNZMQIODW-UHFFFAOYSA-N n-[3-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]phenyl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C=1)=CC=CC=1C(N=1)=NC(N2CC3(COC3)C2)=NC=1N1CCOCC1 UFWUDFNZMQIODW-UHFFFAOYSA-N 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims 2
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000005504 styryl group Chemical group 0.000 claims 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000006799 (C2-C6) alkenylamino group Chemical group 0.000 claims 1
- SLWFMROOKYNKCW-UHFFFAOYSA-N 1-[4-[4-(dimethylamino)piperidine-1-carbonyl]phenyl]-3-[5-[4-morpholin-4-yl-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl]pyridin-2-yl]urea Chemical compound C1CC(N(C)C)CCN1C(=O)C(C=C1)=CC=C1NC(=O)NC1=CC=C(C=2N=C(N=C(N=2)N2CC3(COC3)C2)N2CCOCC2)C=N1 SLWFMROOKYNKCW-UHFFFAOYSA-N 0.000 claims 1
- PURNIHSRWGYONZ-UHFFFAOYSA-N 2-(difluoromethyl)-1h-benzimidazole Chemical compound C1=CC=C2NC(C(F)F)=NC2=C1 PURNIHSRWGYONZ-UHFFFAOYSA-N 0.000 claims 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- YLKHVKXTIXZXRI-UHFFFAOYSA-N 2-pyrimidin-5-ylpyrimidine Chemical compound N1=CC=CN=C1C1=CN=CN=C1 YLKHVKXTIXZXRI-UHFFFAOYSA-N 0.000 claims 1
- BXNDUOXZCCBUDQ-UHFFFAOYSA-N 4-[4-[2-(difluoromethyl)benzimidazol-1-yl]-1,3,5-triazin-2-yl]morpholine Chemical compound FC(F)C1=NC2=CC=CC=C2N1C(N=1)=NC=NC=1N1CCOCC1 BXNDUOXZCCBUDQ-UHFFFAOYSA-N 0.000 claims 1
- NVZWMJWMTWOVNJ-UHFFFAOYSA-N 6-azaspiro[3.4]octane Chemical compound C1CCC21CNCC2 NVZWMJWMTWOVNJ-UHFFFAOYSA-N 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- 239000004593 Epoxy Substances 0.000 claims 1
- XPBBOVRFBHWDGY-UHFFFAOYSA-N NC(N=C1)=NC=C1C1=NC(N(C2)CC22COC2)=NC=C1 Chemical compound NC(N=C1)=NC=C1C1=NC(N(C2)CC22COC2)=NC=C1 XPBBOVRFBHWDGY-UHFFFAOYSA-N 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- FAUSIKJSTFZHHX-UHFFFAOYSA-N [2-methoxy-5-[4-morpholin-4-yl-2-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyrido[2,3-d]pyrimidin-7-yl]phenyl]methanol Chemical compound C1=C(CO)C(OC)=CC=C1C1=CC=C(C(=NC(=N2)N3CC4(COC4)C3)N3CCOCC3)C2=N1 FAUSIKJSTFZHHX-UHFFFAOYSA-N 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 1
- 150000003857 carboxamides Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003463 hyperproliferative effect Effects 0.000 claims 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- GBCKRQRXNXQQPW-UHFFFAOYSA-N n,n-dimethylprop-2-en-1-amine Chemical compound CN(C)CC=C GBCKRQRXNXQQPW-UHFFFAOYSA-N 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1004200.0 | 2010-03-15 | ||
| GBGB1004200.0A GB201004200D0 (en) | 2010-03-15 | 2010-03-15 | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
| PCT/IB2011/051047 WO2011114275A1 (en) | 2010-03-15 | 2011-03-11 | Spirocyclic compounds and their use as therapeutic agents and diagnostic probes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522286A JP2013522286A (ja) | 2013-06-13 |
| JP2013522286A5 true JP2013522286A5 (enExample) | 2014-04-17 |
Family
ID=42261530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557645A Pending JP2013522286A (ja) | 2010-03-15 | 2011-03-11 | スピロ環化合物ならびに治療薬及び診断プローブとしてのその使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130040934A1 (enExample) |
| EP (1) | EP2547684A1 (enExample) |
| JP (1) | JP2013522286A (enExample) |
| KR (1) | KR20130086520A (enExample) |
| CN (1) | CN102939292A (enExample) |
| AU (1) | AU2011228703A1 (enExample) |
| BR (1) | BR112012023320A2 (enExample) |
| CA (1) | CA2791737A1 (enExample) |
| GB (1) | GB201004200D0 (enExample) |
| MX (1) | MX2012010655A (enExample) |
| NZ (1) | NZ602292A (enExample) |
| RU (1) | RU2012143689A (enExample) |
| SG (1) | SG184062A1 (enExample) |
| WO (1) | WO2011114275A1 (enExample) |
| ZA (1) | ZA201206580B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2645968T3 (es) | 2011-09-27 | 2017-12-11 | Novartis Ag | 3-(pirimidin-4-il)-oxazolidin-2-onas como inhibidores de IDH mutante |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| AU2014229313B2 (en) | 2013-03-14 | 2016-07-28 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| AR096151A1 (es) * | 2013-05-01 | 2015-12-09 | Hoffmann La Roche | Compuestos de biheteroarilo y usos de los mismos |
| CN103483345B (zh) * | 2013-09-25 | 2016-07-06 | 中山大学 | Pi3k激酶抑制剂、包含其的药物组合物及其应用 |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| CN104557871B (zh) * | 2013-10-28 | 2017-05-03 | 上海汇伦生命科技有限公司 | 具有螺环取代基的芳基吗啉类化合物，其制备方法和用途 |
| CA2946552A1 (en) | 2014-04-25 | 2015-10-29 | Bluebird Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
| SG10201809379UA (en) | 2014-04-25 | 2018-11-29 | Bluebird Bio Inc | Mnd promoter chimeric antigen receptors |
| SMT202100049T1 (it) * | 2014-06-06 | 2021-03-15 | Bluebird Bio Inc | Composizioni di cellule t migliorate |
| SG11201700492SA (en) | 2014-07-24 | 2017-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
| JP2017532364A (ja) | 2014-10-31 | 2017-11-02 | インディビオール・ユー・ケイ・リミテッド | ドーパミンｄ３レセプターのアンタゴニスト化合物 |
| WO2016094304A2 (en) | 2014-12-12 | 2016-06-16 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| WO2017099712A1 (en) | 2015-12-07 | 2017-06-15 | Bluebird Bio, Inc. | Improved t cell compositions |
| EP3231799A1 (en) * | 2016-04-14 | 2017-10-18 | Universität Basel | 4-(azetidin-1-yl)pyrimidine derivatives with anti-mitotic and anti-proliferative activity |
| US12109234B2 (en) | 2016-11-04 | 2024-10-08 | 2Seventy Bio, Inc. | Anti-BCMA CAR T cell compositions |
| US11339181B2 (en) * | 2016-12-21 | 2022-05-24 | Japan Tobacco Inc. | Crystalline forms of a Janus kinase inhibitor |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EP3573970A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| EP3630747A1 (en) | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| BR112020008991A2 (pt) * | 2017-11-06 | 2020-11-17 | Medshine Discovery Inc. | compostos de piridopirimidina que atuam como inibidores duais de mtorc 1/2 |
| CN108191837A (zh) * | 2018-01-10 | 2018-06-22 | 贵州医科大学 | PI3Kα/mTOR双激酶抑制剂及其药物组合物和应用 |
| CN112584833A (zh) * | 2018-08-01 | 2021-03-30 | 亚瑞克西斯制药公司 | 杂环螺化合物及其用于治疗癌症的使用方法 |
| AU2020398215A1 (en) * | 2019-12-04 | 2022-06-16 | Chdi Foundation, Inc. | ATM kinase inhibitors and compositions and methods of use thereof |
| TW202525813A (zh) * | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| WO2022083569A1 (en) * | 2020-10-20 | 2022-04-28 | Amgen Inc. | Heterocyclic spiro compounds and methods of use |
| WO2025137105A1 (en) * | 2023-12-22 | 2025-06-26 | Deciphera Pharmaceuticals, Llc | Dual raf and tubulin inhibitors and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002253619B2 (en) | 2001-04-27 | 2007-05-17 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same active ingredients |
| EP1877388A2 (en) * | 2005-02-25 | 2008-01-16 | Kudos Pharmaceuticals Ltd | Hydrazinomethyl, hydrazonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents |
| GB0525081D0 (en) * | 2005-12-09 | 2006-01-18 | Astrazeneca Ab | Pyrimidine derivatives |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| EP2064203A1 (en) | 2006-09-14 | 2009-06-03 | AstraZeneca AB | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
| EA200901065A1 (ru) * | 2007-02-06 | 2010-02-26 | Новартис Аг | Ингибиторы pi 3-киназы и способы их применения |
| GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
| CN102056927B (zh) * | 2008-05-13 | 2014-06-25 | Irm责任有限公司 | 作为激酶抑制剂的稠合含氮杂环及其组合物 |
| AP2775A (en) | 2008-05-23 | 2013-09-30 | Wyeth Llc | Triazine compounds as P13 kinase and MTOR inhibitors |
-
2010
- 2010-03-15 GB GBGB1004200.0A patent/GB201004200D0/en not_active Ceased
-
2011
- 2011-03-11 CN CN2011800239958A patent/CN102939292A/zh active Pending
- 2011-03-11 MX MX2012010655A patent/MX2012010655A/es not_active Application Discontinuation
- 2011-03-11 SG SG2012068094A patent/SG184062A1/en unknown
- 2011-03-11 RU RU2012143689/04A patent/RU2012143689A/ru not_active Application Discontinuation
- 2011-03-11 KR KR1020127026689A patent/KR20130086520A/ko not_active Withdrawn
- 2011-03-11 CA CA2791737A patent/CA2791737A1/en not_active Abandoned
- 2011-03-11 BR BR112012023320A patent/BR112012023320A2/pt not_active IP Right Cessation
- 2011-03-11 US US13/635,016 patent/US20130040934A1/en not_active Abandoned
- 2011-03-11 JP JP2012557645A patent/JP2013522286A/ja active Pending
- 2011-03-11 NZ NZ602292A patent/NZ602292A/en not_active IP Right Cessation
- 2011-03-11 WO PCT/IB2011/051047 patent/WO2011114275A1/en not_active Ceased
- 2011-03-11 AU AU2011228703A patent/AU2011228703A1/en not_active Abandoned
- 2011-03-11 EP EP11715742A patent/EP2547684A1/en not_active Withdrawn
-
2012
- 2012-09-03 ZA ZA2012/06580A patent/ZA201206580B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522286A5 (enExample) | ||
| RU2012143689A (ru) | Спироциклические соединения и их применение в качестве терапевтических агентов и диагностических зондов | |
| JP7337174B2 (ja) | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体 | |
| US12138263B2 (en) | Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof | |
| KR102614872B1 (ko) | Hpk1 억제제 및 이의 사용 방법 | |
| CA2969090C (en) | Triazolopyrimidine compounds and uses thereof | |
| US20220331297A1 (en) | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides | |
| KR101331341B1 (ko) | Ｐｉ３ 키나제 및 ｍｔｏｒ 억제제로서의 트리아진 화합물 | |
| RU2345996C1 (ru) | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения | |
| US20200392161A1 (en) | Shp2 phosphatase inhibitors and methods of use thereof | |
| CA3085590A1 (en) | Substituted indole compounds useful as tlr inhibitors | |
| CA3085346A1 (en) | Amide substituted indole compounds useful as tlr inhibitors | |
| JP2011500702A5 (enExample) | ||
| JP7539892B2 (ja) | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 | |
| AU2018233402A1 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| JP2011510010A (ja) | ３Ｈ−［１，２，３］トリアゾロ［４，５−ｄ］ピリミジン化合物、ｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのそれらの使用、ならびにそれらの合成 | |
| NZ603896A (en) | 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia | |
| US20220204498A1 (en) | Pyrido-pyrimidinyl compounds and methods of use | |
| JP2022539208A (ja) | チロシンキナーゼ非受容体１（ｔｎｋ１）阻害剤およびその使用 | |
| JPWO2022008911A5 (enExample) | ||
| WO2021168521A1 (en) | Inhibitors of necroptosis | |
| CA2989684C (en) | Hpk1 inhibitors and methods of using same | |
| HK1255833B (en) | Hpk1 inhibitors and methods of using same |